NeoGenomics (NEO) reported strong first-quarter results, with total revenue reaching $186.7 million, an 11% year-over-year increase that surpassed prior guidance. Clinical revenue surged by 14% to $171.2 million, driven by higher demand and increased average unit prices. Notably, Next-Generation Sequencing (NGS) revenue grew 26%, now comprising about one-third of clinical revenue, positioning the company favorably within the rapidly expanding oncology diagnostics market.
The company’s adjusted EBITDA rose 27% to $9 million, reflecting improved operational efficiency despite a slight decline in adjusted gross margin due to acquisition-related dilution. NeoGenomics also announced an increase in full-year revenue guidance to between $797 million and $803 million, bolstered by the recent MolDX approval for its PanTracer Liquid product and the launch of RADAR ST, which targets molecular residual disease detection.
For market professionals, the key takeaway is NeoGenomics’ strategic shift towards higher-value tests and its robust growth trajectory in NGS, which may enhance competitive positioning and drive sustained revenue growth amid evolving oncology treatment paradigms.
Source: fool.com